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Abstract: Cardiac Troponin T (TnT) is a
regulatory contractile protein not normally
found in blood. Its detection in the circulation
has been shown to be a sensitive and specific
marker for myocardial cell damage. This
study was designed to evaluate the diagnostic
efficiency of TnT enzyme immunoassay for
the early diagnosis of AMI (Acute Myocardial
Infarction) and to compare this newly developed test with the conventionally used cardiac enzyme tests in need of an alternative
test of greater sensitivity and specificity.

TnT appeared in circulation slightly earlier
than CPK and CK-MB and increased to a peak
value of 46 times the detection limit during
the first day. Relative peak values of TnT after onset of pain were 6.4 and 6.8 fold
higher than CK-MB and CPK results. The sensitivity of TnT for detecting AMI was 100%
from the 4th hour to the 100-130th hour after the onset of symptoms and the diagnostic
sensitivity of TnT was superior to that of
CPK and CK-MB (100% versus 23% and
15%).

The study population consisted of 13 patients
with a mean age of 52±8 years who were
hospitalized for AMI. Blood samples for TnT,
CPK and CK-MB measurements were drawn
at the time of admission (2.9±1.7 hours after the onset of chest pain) and at the 4th,
14-16th, 32-34th and 100-130th hours
thereafter. We used an enzyme immunologic
assay for the quantitative determination of
serum TnT and enzymatic methods for CPK
and CK-MB.

Thus the results of this study indicate that;
TnT test improves the efficiency of
serodiagnostic tools in detection of AMI and
gives a larger diagnostic window that allows
serological detection of subacute myocardial
infarction.

Departments of 1Biochem, Ege Univ. Medical
Faculty Cardiology 2Buca SSK Hospital Dept. of
Biochem, Buca-İzmir-Turkey

Introduction
Acute myocardial infarction (AMI) is a medical
emergency and continues to be the major cause of
cardiovascular morbidity and death even nowadays
(1,2). The diagnosis of AMI is usually straightforward
and based on the peresence of two of three classic
findings; 1) a history of characteristic chest pain, 2)
evolutionary changes on the ECG and, 3) increased
serum concentrations of cardiac enzymes, especially CK
isoenzyme MB (2-5).
The measurement of CK-MB is currently the test
of choice for the confirmation or exclusion of the diagnosis of AMI (6,7) Though CK-MB determination is
an excellent tool for the diagnosis of AMI in the majority of patients, in certain groups (eg. those who do
not seek early medical attention, those with concomitant skeletal muscle injury), AMI is often more
difficult to assess (5). Yet, variable normal serum
levels of CK-MB, its presence in noncardiac muscular
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tissues, and its small and short-lasting increase in serum during the course of MI limits the diagnostic value
of CK-MB determination (8).
Recently, Katus et al. developed an enzyme immunoassay for the cardiac Tn T isoform, which
showed a cross-reactivity with Tn T extracted from
mixed skeletal muscle of only 1-2% (2,3,8-10) and by
using this assay, they provided evidence that measurement of serum Tn T levels offers a diagnostic advantage over CK-MB in the subgroups of patients
mentioned above (5,6,8).
Cardiac TnT is a 37-kDa polypeptide subunit of the
myofibrillar regulatory troponin complex (9,11). Because the amino acid sequence is unique to cardiac
muscle, it is immunologically possible to differentiate
skeletal muscle and cardiac protein isoforms (3,9,12).
In the cardiomyocyte, TnT is compartmentalized into a
minor cytosolic (5%) and a major myofibrillary bound
(95%) fraction (9). When the myocytes are damaged,
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loss of cell membrane integrity occurs and proteins of
the cardiac contractile apparatus diffuse first into the
interstitium and subsequently into the intravascular
space and lymphatics (5,13). Their pattern of appearance in blood depends on their intracellular location,
molecular weight, local blood and lymph flow and the
rate of elimination from the blood (5).
Cardiac Tn T is one of these regulatory contractile
proteins not normally found in blood (8, 14,15). In a
group of recent studies its detection in the circulation
has been shown to be a sensitive and specific marker
for myocardial cell damage (12,14,16).
The aim of this study is to evaluate the diagnostic
efficiency of Tn T enzyme immunoassay for the early
and subacute diagnosis of AMI and to compare this
newly developed test with the conventionally used cardiac enzyme tests in need of an alternative test of
greater sensitivity and specificity.
Materials and Methods
The study population consisted of 13 patients (12
men and a woman) with a mean age of 52±8 years
who were hospitalized in Coronary Intensive Care Unit
of Cardiology Department of Ege University Medical
Faculty, İzmir, Turkey for AMI. Only the patients suffering from chest pain that met electrocardiographic
and enzymatic criteria of the World Health Organization were included in the study. Patients who have
stable or unstable angina pectoris or other cardiovascular disorders were not included in the study.
All the patients were given bed rest and an intensive
medical regimen that included nitrates, beta-blockers,
calcium-channel blockers and intravenous thrombolytic
therapy. Standart 12-lead electrocardiography (ECG)
was performed routinely at the time of admission and
thereafter. The procedures followed in the study were
in accord with the ethical standards of the committee
on human experimentation of the hospital of Ege University Medical Faculty.
Blood samples for Tn T, CPK and CK-MB measurements were drawn at the time of admission (2.9±1.7
hours after the onset of chest pain) and at the 4th,
14-16th , 32-34th and 100-130th hours thereafter.
Blood samples were stored at room temperature for
30 minutes to allow clotting. After centrifugation at
5000 g for 10 minutes, the serum samples were
stored frozen at -30˚C as aliquots for a maximum of
two months until the analysis were done.
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For the quantitative determination of serum Tn T,
an enzyme immunoassay (ELISA Troponin T; Boehringer Mannheim) was used. Based on a technique using
spreptavidin, this single step sandwich assay allows serial determination of blood samples to be made within
two hours (3,8,9,12,17).
The test requires streptavidin-coated tubes as the
solid phase and two monoclonal antihuman cardiac
TnT antibodies (12,17). During 60-minutes incubation
period, the antigen (in this case, TnT in patient’s serum) is bound by one biotinylated and one peroxidaselabeled antibodies. This complex adheres to the
test-tube wall because of the high-affinity streptavidinbiotin interaction. After two washing steps, the substrate chromogen solution (ABTS) is added. Substrate
conversion is quantified by the occurrence of a change
in color at 420 nm. Measurements were made against
substrate-chromogen solution as blank with a LKB
spectrophotometer using semimicro cuvette of 1.0 cm
light path. For TnT, the reference interval (0.0-0.2
ng/ml) was established from samples of ten healthy
blood donors from laboratory staff and values greater
than 0.20 ng/ml were considered positive for AMI.
Catalytic activities of CPK and CK-MB were
measured at 37˚C with a Hitachi 705 autoanalyser using commercial reagent supplied by Boehringer Mannheim (CK-NAC activated and CK-MB NAC activated,
respectively). The upper reference limits used for
these assays were 190 U/L for CPK and 24 U/L for
CK-MB at 37˚C.
Data Analysis:
The history of the patients, 12-lead ECG were
evaluated by cardiologists, who were unaware of the
serological test results. The test results are expressed
as “relative increases” which is defined as the ratios of
the patients serum activities (mean±SEM) to the upper
limit of normal in the case of CPK and CK-MB or to
the analytical sensitivity of the TnT test (0.2 ng/ml).
Also, the results are expressed in terms of “sensitivity”
which is defined as the number of true positive test
results in all patients with AMI and “specificity” as the
number of true negative test results in all healthy
blood donors without AMI.
Results
The mean±SEM values of cardiac marker proteins
(TnT, CPK and CK-MB) after hospital admission of the
patients with AMI were presented in Table 1.
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Figure 1.
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32-34th hour 100-130th hour

The mean±SEM values of TnT, CPK and CPK-MB after
hospital admission of the patients with AMI.
TnT

CPK

CK-MB

ng/ml

U/L

U/L

At admission

0.33±0.14

138.9±36.5

16.2±2.4

4 th hour

8.26±2.53

1366.4±300.1

135.5±26.8

14-16 th hour

9.22±1.57

1290.6±184.8

172.0±56.0

32-34 th hour

5.54±1.19

483.7±98.7

40.2±8.0

100-130 th hour

2.69±0.55

110.7±23.7

12.8±4.2

Table
It shows the relative increase of the mean±SEM values and the
diagnostic sensitivity of TnT, CPK and CK-MB in patients with AMI.
Blood Sampling

The relative increase of the mean±SEM values and
the diagnostic sensitivity of the cardiac marker proteins by time in AMI were presented in Table 2 and
were shown in Figure 1 and Figure 2, respectively.

Relative Increase

2.

Diagnostic Sensitivity

TnT

CPK

CK-MB

TnT

CPK

CK-MB

At admission

x1.7

x0.7

x0.7

46%

15%

23%

4th hour

x41.3

x7.2

x5.6

100%

100% 100%

14-16 th hour

x46.2

x6.8

x7.2

100%

100% 100%

32-34 th hour

x27.7

x2.5

x1.7

100%

92%

69%

100-130 th hour

x13.5

x0.6

x0.6

100%

23%

15%

At the time of admission six of the 13 patients
with AMI had elevated TnT values (46%) while only
two of them had elevated CPK (15%) and three of
them had elevated CK-MB activities (23%) (Table 2,
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Figure 2). The patients with and those without
elevated TnT values did not differ with respect to clinical charcteristics and treatment.
At the 4th and 14-16th hours after admission, all
of the patients had elevated TnT values, besides
increased CPK and CK-MB activities (Table 2, Figure
2). However, relative peak value of TnT at the 14-16
th hours was 6.4 and 6.8 fold higher than CK-MB
and CPK values, respectively (Table 2, Figure 1).
At the 32-34th hours after admission TnT was detectable in all of the patients (100%) while CPK activities showed an increase in 12 patients (92%) and
CK-MB was elevated in 9 patient (69%) (Table 2, Figure 2). At the 100-130th hours all of the patients
still had increased TnT values (100%) while only 3 of
them had increased CPK values (23%) and 2 of them
had elevated CK-MB activities (15%) (Table 2, Figure
2).
The specificity of TnT test was evaluated with the
measurement of serum TnT concentrations in controls,
comprised of 10 healthy blood donors from laboratory
staff who do not have cardiac discomfort, and was
found 100%.
Discussion
The diagnosis of AMI has traditionally been based
on the triad of a characteristic clinical history, electrocardiographic abnormalities and increased serum concentrations of cardiac enzymes (3,4). For the early diagnosis of AMI, the diagnostic value of chest pain is
limited. The same is true for specific changes in the
electrocardiographic recordings at admission (8).
Therefore, measurement of biochemical markers has
become a cornerstone in the diagnosis of AMI (11).
However, in pratice, physicians are sometimes left
with patients in whom a definitive diagnosis of MI can
not be made by measurement of conventional plasma
enzymes or isoenzymes (8,18). There are problems
with the diagnosis of small myocardial infarctions,
which from the therapeutic and prognostic points of
view are at least comparable in importance with the
transmural infarctions. The ECG offers little help in
such cases and the sensitivity of the laboratory parameters CPK, CK-MB, lactate dehydrogenase (LD) and
LD1 isoenzyme is not sufficient because of the variations in normal serum levels and of the short-lasting
and small increases in serum activity after such events.
The available diagnostic methods are also unsatisfactory in patients with multiorgan diseases or
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with additional skeletal muscle lesions, because in such
cases a definite differentiation of skeletal muscle and
heart muscle necrosis is impossible because of the organ distribution of CPK and LD or its isoforms. And
also, current diagnostic procedures are unable to give
definite evidence of infarction in patients who arrive at
the hospital in a subacute phase (5).
In recent years, considerable efforts have been
made to improve the specificity and sensitivity of
methods for diagnosing AMI. Myoglobin is an early
and sensitive marker of cardiac cell damage but lacks
specificity. The use of LD and its LD1 isoenzyme
improves specificity in diagnosing AMI; however, these
isoenzymes are not restricted to cardiac muscle tissue
and increases in their serum concentrations have been
observed in noncardiac conditions (3). The sensitivity
of the CK determination is limited because the
increase in serum CK is relatively small, lasts only a
short time after the onset of pain and may be
obscured by differences in normal serum levels. Clinicians would therefore benefit from the introduction
of a new cardiac-specific marker of myocardial muscle
cell damage. A recently introduced alternative, proposed as a very sensitive and specific marker for myocardial damage, is constituted by the immunological
determination of cardiospecific troponin T, a 37 kDa
polypeptide subunit of the myofibrillar regulatory troponin complex (11).
In a group of recent studies, it has been shown
that the diagnostic sensitivity of TnT is considerably
better than that of myoglobin, CPK and CK-MB
activity (11). The biggest advantage of TnT is its cardiospecificity. Thus, measurements are especially helpful in the assessment of patients with myocardial ischemia and skeletal muscle injury-eg, after cardiac
surgery or in multiorgan damage (19).
In an attempt to find a more suitable marker for
myocardial cell damage, we assessed the diagnostic
properties of TnT and compared it with those of the
currently used cardiac enzymes, such as CPK and CKMB. In most of the cases with AMI, TnT appeared in
the circulation within 3 hours after the onset of chest
pain-slightly earlier than the rise in CPK and CK-MB
activities, thus elevated results at admission were encountered more frequently for TnT (46%) than for
CPK (15%) and CK-MB (23%) measurements.
(p<0.01) (Table 2, Figure 2).
It is seen that, our results are in concordance with
the ones of Katus HA et al (8) who had observed
increased serum TnT values in 50% of 388 patients
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admitted with chest pain and suspected AMI as early
as 3 hours after the onset of chest pain and with
those of Mair J et al (3) who had reported a 50%
TnT sensitivity at the 4th hour after the onset of AMI
symptoms.
In a recent report investigating the value of TnT in
early diagnosis of AMI, Bakker AJ et al (11) pointed
out that within 4 hours after onset of chest pain, the
currently used methods for measuring enzyme of CPK
and CK-MB attained a low diagnostic sensitivity (20%
and 16%, respectively) while TnT showed a
considerably higher diagnostic sensitivity (51%) than
that of CPK and CK-MB activities.
Also it is interesting to note that during the first
day, TnT increased to a peak value of 46.2 times the
detection limit, while CPK and CK-MB activities
generally did not increase more than 7.2 fold (Table
2, Figure 1). Concordant with our findings, Katus HA
et al (8) reported that TnT increased to a first peak
value of 40 times the detection limit during the first
day and a peak value of 30 times the detection limit
on about the fourth day, while serum CPK and LD activities only increased to nine and three times the
upper limit of normal, respectively.
The half life of TnT is 120 minutes, so the sustained increase in serum concentration probably
reflects continuing release of this protein from disintegrating myofilaments(19). This apparent superriority of TnT to CPK and CK-MB, probably is due to
a longer diagnostic window rather than to more release of the protein per gram of damaged tissue (6).

100% from the 4th hour of admission to the 100130 th hours and it was still 100% revealing a peak
values of 13.5 times the detection limit on about the
fifth day by contrast to CPK (23%) and CK-MB
(15%) activities which were mostly normalized (Table
2, Figure 1 and 2). Thus, the persistance of the elevation of TnT levels at the 5th day also facilitates retrospective identification of AMI.
These results are in accordance with other investigators’ findings (2,3,5,9,11,19,20) so TnT test
can be proposed as an ideal late marker for diagnosing subacute infarction in patients who only
come to the hospital in the late phase of the infarction, with uncharacteristic symptoms and already
normalized CPK and CK-MB activities.
Based on our finding discussed above, it is
concluded that in addition to the high diagnostic sensitivity and specificity, the early and persistent rise in
serum TnT concentrations provides a wide diagnostic
window offering additional reliability in the diagnosis
of myocardial infarction both in hyperacute and subacute phases.
Thus, the data of this study indicate that the newly
developed TnT test improves the efficiency of
serodiagnostic tools for the detection of myocardial
cell necrosis as compared with conventionally used cardiac enzymes.
It appears that, TnT will be an attractive marker
both for early and late diagnosis of AMI, if more
rapid and cheaper assay methods should be developed
in the near future.

The sensitivity of TnT for detecting AMI was
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